Adverse effects of therapy for ANCA-associated vasculitis
Authors:
- Lorraine HarperLHLorraine Harper
- 1 June 2009
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 23 (3) , 391-401
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosisArthritis Care & Research, 2008
- Teriparatide or Alendronate in Glucocorticoid-Induced OsteoporosisNew England Journal of Medicine, 2007
- Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferaseEuropean Respiratory Journal, 2007
- Disease-Modifying Antirheumatic Drugs in PregnancyDrug Safety, 2006
- Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)Arthritis & Rheumatism, 2005
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005
- ANCA-associated renal vasculitis at the end of the twentieth century—a disease of older patientsRheumatology, 2004
- The value of pulse cyclophosphamide in ANCA‐associated vasculitis: meta‐analysis and critical reviewNephrology Dialysis Transplantation, 2001
- Trimethoprim–Sulfamethoxazole (Co-Trimoxazole) for the Prevention of Relapses of Wegener's GranulomatosisNew England Journal of Medicine, 1996
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992